CeBIL, Faculty of Law, University of Copenhagen, is seeking to appoint a PhD researcher for a fully funded three-year period. We are looking for candidates with innovative and original ideas, and we strive for excellence in quality and originality.
The successful candidate can commence from 1 November 2019 or as soon as possible thereafter.
The Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) explores the legal challenges and the rapid developments in the biotechnological area. CeBIL brings together scholars from some of the world’s leading research institutions in interdisciplinary collaboration as well as stakeholders from industry, government and civil society. Alongside other projects, CeBIL hosts the Collaborative Research Programme for Biomedical Innovation Law (CeBIL Programme). This 5-year research programme (2018-22) is supported by a grant of DKK 35 million from the Novo Nordisk Foundation and involves partners from Cambridge, Harvard Law School,Harvard Medical School, Michigan, and the UCPH IFRO.
The CeBIL Programme focuses on innovation inefficiencies on the life science frontiers through five concrete interrelated studies. The common aim of the five studies is to optimize legal concepts into enabling tools that will help bring novel technologies, research, and biomedicine together for radical innovation – thereby providing much-needed contribution to bridging bio-pharmaceutical innovation gaps, enhancing translational medicine, and promoting technology transfer. An overarching study on Policy & Synergy will ensure continuous knowledge exchange and synergy across the five concrete studies:
Study 1: Antibiotics
Study 2: Orphan Drugs
Study 3: Precision Medicine, Big Data & Artificial Intelligence
Study 4: New Uses
Study 5: Drug Manufacturing & Biologics
Study 6: Policy & Synergy
The objective of the CeBIL Programme is to demonstrate how legal science methods that take careful account of interdisciplinary insights and “real world” perspectives can generate new knowledge about key factors driving pharmaceutical innovation. In addition, such methods will be utilised to examine how innovation incentives, other than patents, can be applied, combined, optimised and conceptualised in order to either substitute or complement patent protection in new areas of crucial medical applications. Within this context, special focus will also be laid on the impact of emerging digital technologies, big data and artificial intelligence.
For more information click "LINK TO ORIGINAL" below